<DOC>
	<DOCNO>NCT01340040</DOCNO>
	<brief_summary>The primary purpose study explore safety tolerability MEDI-573 Japanese subject advance solid tumour refractory standard therapy standard therapy exist .</brief_summary>
	<brief_title>Dose-escalation Study Assess Safety , Tolerability Pharmacokinetics MEDI-573 Japanese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Japanese men woman least 20 year age Histological cytological confirmation solid , malignant tumour exclude lymphoma refractory standard therapy standard therapy exist WHO performance status 02 deterioration previous 2 week Previous therapy medication IGF ( ie , monoclonal antibody IGF1R IGFtargeting tyrosine kinase inhibitor ) Inadequate bone marrow reserve organ function Poorly control diabetes mellitus define investigator 's assessment and/or glycosylated hemoglobin ( HbA1c ) read &gt; 6.5 % within 28 day prior first dose MEDI573 History allergy reaction component MEDI573 formulation drug similar chemical structure class MEDI573</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Phase I</keyword>
	<keyword>cancer</keyword>
	<keyword>solid tumour</keyword>
	<keyword>advanced solid malignancy</keyword>
	<keyword>dose escalation</keyword>
	<keyword>Insulin like growth factor</keyword>
	<keyword>Japanese</keyword>
</DOC>